CA
PLRX icon

CHI Advisors’s Pliant Therapeutics PLRX Stock Holding History

CHI Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$55K Buy
137,500
+7,200
+6% +$125K 0.02% 28
2023
Q2 		$162K Buy
+130,300
New +$3.08M 0.05% 25
2023
Q1 		– Sell
-30,000
Closed -$29.3K – 26
2022
Q4 		$29.3K Buy
+30,000
New +$627K 0.01% 23

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CHI Advisors's PLRX Position: Q3 2023 in Review

CHI Advisors reduced its Pliant Therapeutics (PLRX) stake by 3.3% in Q3 2023, selling an estimated $1.78M and leaving 3,014,199 shares worth $52.3M. The position accounts for 20.72% of the portfolio, ranked #1.

CHI Advisors first reported a position in PLRX in Q2 2020 and has held it in 14 quarters since. The position peaked at $91.4M in Q1 2021. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

  • CHI Advisors held 3,014,199 shares of Pliant Therapeutics worth $52.3M as of Q3 2023.
  • CHI Advisors sold 102,818 Pliant Therapeutics shares in Q3 2023, an estimated $1.78M.
  • Pliant Therapeutics made up 20.72% of CHI Advisors's portfolio in Q3 2023, its #1 holding.
  • CHI Advisors first reported a position in Pliant Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • CHI Advisors's Pliant Therapeutics position peaked at $91.4M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.